Summary
This prediction ended on 19.03.18 with a price of €14.55. The BUY prediction by melinda for GSK plc closed nearly unchanged. melinda has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| GSK plc | 2.007% | 2.007% | 10.775% | 20.025% |
| iShares Core DAX® | -2.196% | -0.532% | 12.492% | 15.176% |
| iShares Nasdaq 100 | -0.074% | 1.843% | 40.598% | 43.702% |
| iShares Nikkei 225® | -2.154% | -1.109% | 22.295% | 3.143% |
| iShares S&P 500 | -0.501% | 1.475% | 28.278% | 41.943% |
According to melinda what are the pros and cons of GSK plc for the foreseeable future?
Pros
Could be worthwhile Investment >10% per year
Cons
Comments by melinda for this prediction
In the thread GlaxoSmithKline plc diskutieren
Pharmazeutische SecteurProduits Agenda 25/04 Ergebnisse Veröffentlichung
GSK stellt fest , dass ViiV Healthcare verkündet positive Daten Dolutegravir
5. März (Reuters) - Glaxosmithkline Plc :: GLAXOSMITHKLINE PLC - ViiV Healthcare KÜNDIGT NEUE DATEN ZUR BEHANDLUNG VON MENSCHEN POSITIVE Dolutegravir mit HIV-Infizierte mit TUBERCULOSIS.GLAXOSMITHKLINE CO PLC - Dolutegravir WANN 50mg zweimal täglich zu MIT NUCLEOSID DOUBLE REVERSE.